Acrivon Therapeutics Inc (NASDAQ: ACRV) on Friday, plunged -4.55% from the previous trading day, before settling in for the closing price of $1.10. Within the past 52 weeks, ACRV’s price has moved between $1.06 and $10.16.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 7.47%. With a float of $22.16 million, this company’s outstanding shares have now reached $31.35 million.
Let’s look at the performance matrix of the company that is accounted for 78 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Acrivon Therapeutics Inc (ACRV) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Acrivon Therapeutics Inc is 29.34%, while institutional ownership is 56.77%. The most recent insider transaction that took place on Apr 30 ’25, was worth 617,412. In this transaction 10% Owner of this company sold 437,881 shares at a rate of $1.41, taking the stock ownership to the 3,403,025 shares. Before that another transaction happened on May 01 ’25, when Company’s 10% Owner sold 298,886 for $1.34, making the entire transaction worth $400,507. This insider now owns 3,104,139 shares in total.
Acrivon Therapeutics Inc (ACRV) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 7.47% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 3.46% during the next five years compared to -74.96% drop over the previous five years of trading.
Acrivon Therapeutics Inc (NASDAQ: ACRV) Trading Performance Indicators
Acrivon Therapeutics Inc (ACRV) is currently performing well based on its current performance indicators. A quick ratio of 11.17 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.22, a number that is poised to hit -0.57 in the next quarter and is forecasted to reach -2.31 in one year’s time.
Technical Analysis of Acrivon Therapeutics Inc (ACRV)
Acrivon Therapeutics Inc (NASDAQ: ACRV) saw its 5-day average volume 0.63 million, a positive change from its year-to-date volume of 0.45 million. As of the previous 9 days, the stock’s Stochastic %D was 12.43%. Additionally, its Average True Range was 0.14.
During the past 100 days, Acrivon Therapeutics Inc’s (ACRV) raw stochastic average was set at 0.00%, which indicates a significant increase from 0.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 66.37% in the past 14 days, which was lower than the 159.35% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.8256, while its 200-day Moving Average is $5.6398. Nevertheless, the first resistance level for the watch stands at $1.1100 in the near term. At $1.1700, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.2000. If the price goes on to break the first support level at $1.0200, it is likely to go to the next support level at $0.9900. The third support level lies at $0.9300 if the price breaches the second support level.
Acrivon Therapeutics Inc (NASDAQ: ACRV) Key Stats
Market capitalization of the company is 32.92 million based on 31,355K outstanding shares. Right now, sales total 0 K and income totals -80,560 K. The company made 0 K in profit during its latest quarter, and -19,680 K in sales during its previous quarter.
